Home

Biologics for Cosmetic Surgery.

Exosomes and Wharton’s Jelly applied in conjunction with the procedures you already offer, sourced directly from an FDA-registered lab with full documentation on every order.

Your patients expect premium. Your biologics source should match.

Post-operative appearance is an increasingly cited factor in patient satisfaction and referrals. Providers who can document their biologic source, explain what’s in the vial, and answer patient questions about quality and safety are positioned differently than those who can’t.

Biologics ship direct from our FDA-registered lab with a Certificate of Analysis and full chain-of-custody documentation included on every order.

Cosmetic surgery

How Biologics Integrate Into Your Procedures

Facelifts

Wharton’s Jelly applied during closure. Natural collagens and human-derived hyaluronic acid are homologous to components naturally present in facial soft tissue. A 2024 peer-reviewed review in Plastic and Reconstructive Surgery – Global Open observed positive collagen synthesis and reduced erythema in post-surgical exosome applications.¹

Rhinoplasty

Applied to soft tissue at provider direction during recovery. Natural collagens and 200+ biologically active growth factors homologous to components naturally present at the treatment site.¹

Body Contouring

Applied post-procedure at provider direction. Approximately 350 billion exosomes per cc, natural human-derived hyaluronic acid, and chondroitin sulfate, components homologous to those naturally present in soft tissue.

Breast Augmentation

Wharton’s Jelly applied at the treatment site at provider direction. Natural collagens, human-derived hyaluronic acid, and chondroitin sulfate are homologous to components naturally present in surrounding soft tissue.²

Post-Surgical Site Care

Applied at surgical sites at provider direction. Natural collagen and human-derived hyaluronic acid in a viscous scaffold matrix, keeping the full bioactive complement localized at the application site.

Skin Resurfacing

Applied in conjunction with laser and resurfacing procedures. Exosomes and Wharton’s Jelly deliver natural collagens, hyaluronic acid, and growth factors homologous to components naturally present in healthy skin.

Revenue Potential

Model the financial impact of adding regenerative biologics to your surgical practice.

$1–5K
Avg Add-On
8–20
Monthly Volume
$96K–1.2M
Annual Potential

Products for Cosmetic Surgeons

Wharton's Jelly
  • 200+ biologically active cytokines and growth factors
  • Natural collagens
  • Human-derived hyaluronic acid
  • Chondroitin sulfate
  • Viscous scaffold matrix, stays localized at the treatment site
Exosomes
  • ~350 billion exosomes per cc
  • 300+ biologically active cytokines and growth factors
  • Natural human Klotho
  • Human-derived hyaluronic acid
  • Chondroitin sulfate
FDA
FDA Registered
cGMP
cGMP Facility
ISO
Class 5 & 7 Cleanroom
MoCRA
MoCRA Compliant
Ethically Sourced

Ready to elevate your surgical protocols?

Position your practice at the forefront of regenerative aesthetics. Science-backed biologics. Premium patient experience.

Citations

1 Kalinichenko SG, et al. “Exosome-mediated Advancements in Plastic Surgery: Navigating Therapeutic Potential in Skin Rejuvenation and Wound Healing.” Plastic and Reconstructive Surgery – Global Open. August 2024. pmc.ncbi.nlm.nih.gov/articles/PMC11556992/

Built by AUSTAN

DISCLAIMER

Sōlix does not own, operate, or manage any laboratory, manufacturing, or compounding facility. All biological products available through this platform are manufactured, processed, and distributed by our independently owned and operated FDA-registered laboratory partners. Sōlix does not distribute, ship, handle, or take possession of any biological product at any point in the supply chain.

Sōlix operates as a provider platform that offers licensed healthcare practitioners access to product ordering, clinical education, implementation support, marketing resources, and business integration tools designed to help practices incorporate regenerative biologics into their clinical offerings.

Sōlix is not a compounding pharmacy or chemical compounding facility as defined under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Sōlix does not compound, manufacture, repackage, or relabel any drug or biological product.

Sōlix resources are for educational and informational purposes only. Providers are responsible for their own regulatory compliance, licensing, and insurance. Sōlix assumes no liability for how materials are applied in practice.

FDA DISCLAIMER

The statements made on this website have not been evaluated by the U.S. Food and Drug Administration. The products and services referenced on this platform are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Biological products, including but not limited to stem cells, exosomes, Wharton's Jelly, and amniotic tissue allografts, are minimally manipulated human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated under 21 CFR Part 1271. These products are intended for homologous use only and are administered at the sole discretion of a licensed healthcare provider following individual patient assessment. Results may vary. No guarantees of specific outcomes are made or implied.

All medical decisions, including the use of regenerative biologics, should be made in consultation with a qualified healthcare professional. Sōlix makes no medical claims and assumes no liability for clinical outcomes resulting from the use of products ordered through this platform.

Sōlix provides a provider platform and sales CRM for ordering regenerative human biologics, managing provider relationships, and integrating third-party services including Google Calendar for scheduling and appointment management. For details on how we handle your data, see our Privacy Policy.

Terms & ConditionsPrivacy Policy